Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Alector, Inc.

35 indications, side-by-side phase, drug & LoA

$1.53

-0.04 (-2.55%)

C 42Pipeline Score Undervalued Biotech · Commercial
Market Cap
216.50 M
EPS
-1.19
P/E Ratio
-1.64 $
Value Trade
3.00 M
SEC Financials
Q1 2026

  • Dilution Risk

    50%

  • Revenue

    1.05 M

  • R&D Expenses

    17.86 M

  • Operating CF

    -49.81 M

  • Total Assets

    239.92 M

  • Total Liabilities

    229.53 M

  • Equity

    10.38 M

  • D/E Ratio

    12,345

-1.34 %
Week
-10.89 %
1 Month
12.18 %
3 Month
84.17 %
6 Month
-87.29 %
5 Year
-88.18 %
All Time
Cash Data
Caution

  • Cash Position

    206.51 M

  • Monthly Burn

    16.60 M

  • Runway

    11.3 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
263.83 K
52 Week Range
1.09 - 3.40
% held by Insiders
30.06 %
% held by Institutions
61.95 %
Enterprise Value
44.53 M
Total Shares
109.18 M
Short %
6.13 %
Float Shares
82.98 M
Company Description
HQ: 131 OYSTER POINT BLVD., SUITE ...
Founded:2013
Employees:103
https://www.alector.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C42
Pipeline Score
$208M
Pipeline Value
Undervalued
Valuation Signal
4
Drugs Scored
3.2x
rNPV / MCap
Top 57%
Micro Cap
(rank 390 of 905)
Percentile Rank
Alector, Inc. carries a moderate pipeline score (42/100), with $4.5B risk-adjusted pipeline value, led by AL001 in Frontotemporal Dementia (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
AL001
Small molecule		Frontotemporal DementiaPhase 2NCT0398729521% $3.0B COMPLETED 33 - -Jun 5, 2024 -Dec 5, 2025
Unlock Drug Pipeline Intelligence
ALEC Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ALEC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Alector, Inc. (ALEC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ALEC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALEC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALEC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ALEC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ALEC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Alector, Inc. (ALEC) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ALEC ranks across every disease it competes in
No competitive intelligence available for ALEC.